








## Future Blockbusters in Brief

Product	Developer	Status
<b>Brilinta (ticagrelor)</b>	AstraZeneca 	Awaiting regulatory approval in the United States for the reduction of major adverse cardiac events in patients with acute coronary syndrome and in Europe for the treatment of arterial thrombosis
<b>BG-12/BG00012 (dimethyl fumarate)</b>		Phase III trials in the United States and Europe for the treatment of relapsing-remitting multiple sclerosis, and Phase II trials, in combination with methotrexate, for the treatment of patients with active rheumatoid arthritis who had an inadequate response to conventional disease-modifying antirheumatic drug therapy
<b>QABI49 (indacaterol)</b>		Awaiting FDA approval for the treatment of chronic obstructive pulmonary disease
<b>Mipomersen</b>	genzyme and 	Phase III trials in the United States for the treatment of heterozygous familial hypercholesterolemia, the treatment of hypercholesterolemic patients on maximally tolerated dosages of statins who are at high risk for coronary heart disease, and for the treatment of severe hypercholesterolemia who are on a maximally tolerated lipid-lowering regimen; Phase II trials for the treatment of high-risk, high-cholesterol patients who are intolerant to statins
<b>Taspoglutide</b>		Phase III clinical trials in the United States for the treatment of Type 2 diabetes

\*Adapted from *Med Ad News*, February 2010

CPM